Tags

Type your tag names separated by a space and hit enter

Calcitonin versus cimetidine or De-Nol in gastric ulcer treatment. An endoscopically controlled trial.
Dtsch Z Verdau Stoffwechselkr. 1988; 48(5):239-43.DZ

Abstract

110 patients with benign gastric ulcer and concomitant joint diseases (rheumatoid arthritis, osteoarthrosis) were treated in a comparative short-term clinical trial to assess the relative efficacy of calcitonin (daily 100 MRC of salmon calcitonin intramuscularly), cimetidine (daily 1000 mg orally) and colloidal bismuth subcitrate (De-Nol-four times a day in doses of 5 ml diluted with 15 ml of water). Groups of patients were comparable according to age, sex, duration of ulcer disease, smoking habits, gastric acid secretion and mean ulcer size. The ulcer healing was controlled endoscopically after 2 and 4 weeks of the treatment. There was no significant difference in the ulcer healing rate between three groups neither after 2 weeks (calcitonin-36.7% of healed ulcers, cimetidine-37.5% and De-Nol-35.0% nor after 4 weeks respectively (76.7%, 72.5% and 77.5%). In the calcitonin group a gradual joint pain relief was observed in 84% of patients who complained arthralgia. The moderate side effects (headache, nausea, flush) were observed only in the patients treated with calcitonin (8 subjects). We suggest that calcitonin may be considered as a valid anti-ulcer drug in the peptic ulcer patients with concomitant rheumatological diseases especially with osteoporosis.

Authors+Show Affiliations

Department of Gastroenterology, J. Sniadecki's Regional Hospital, Białystok.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

3075178

Citation

Janke, A, et al. "Calcitonin Versus Cimetidine or De-Nol in Gastric Ulcer Treatment. an Endoscopically Controlled Trial." Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten, vol. 48, no. 5, 1988, pp. 239-43.
Janke A, Badurski J, Stasiewicz J, et al. Calcitonin versus cimetidine or De-Nol in gastric ulcer treatment. An endoscopically controlled trial. Dtsch Z Verdau Stoffwechselkr. 1988;48(5):239-43.
Janke, A., Badurski, J., Stasiewicz, J., Sajewicz, I., & Namiot, Z. (1988). Calcitonin versus cimetidine or De-Nol in gastric ulcer treatment. An endoscopically controlled trial. Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten, 48(5), 239-43.
Janke A, et al. Calcitonin Versus Cimetidine or De-Nol in Gastric Ulcer Treatment. an Endoscopically Controlled Trial. Dtsch Z Verdau Stoffwechselkr. 1988;48(5):239-43. PubMed PMID: 3075178.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Calcitonin versus cimetidine or De-Nol in gastric ulcer treatment. An endoscopically controlled trial. AU - Janke,A, AU - Badurski,J, AU - Stasiewicz,J, AU - Sajewicz,I, AU - Namiot,Z, PY - 1988/1/1/pubmed PY - 1988/1/1/medline PY - 1988/1/1/entrez SP - 239 EP - 43 JF - Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten JO - Dtsch Z Verdau Stoffwechselkr VL - 48 IS - 5 N2 - 110 patients with benign gastric ulcer and concomitant joint diseases (rheumatoid arthritis, osteoarthrosis) were treated in a comparative short-term clinical trial to assess the relative efficacy of calcitonin (daily 100 MRC of salmon calcitonin intramuscularly), cimetidine (daily 1000 mg orally) and colloidal bismuth subcitrate (De-Nol-four times a day in doses of 5 ml diluted with 15 ml of water). Groups of patients were comparable according to age, sex, duration of ulcer disease, smoking habits, gastric acid secretion and mean ulcer size. The ulcer healing was controlled endoscopically after 2 and 4 weeks of the treatment. There was no significant difference in the ulcer healing rate between three groups neither after 2 weeks (calcitonin-36.7% of healed ulcers, cimetidine-37.5% and De-Nol-35.0% nor after 4 weeks respectively (76.7%, 72.5% and 77.5%). In the calcitonin group a gradual joint pain relief was observed in 84% of patients who complained arthralgia. The moderate side effects (headache, nausea, flush) were observed only in the patients treated with calcitonin (8 subjects). We suggest that calcitonin may be considered as a valid anti-ulcer drug in the peptic ulcer patients with concomitant rheumatological diseases especially with osteoporosis. SN - 0012-1053 UR - https://www.unboundmedicine.com/medline/citation/3075178/Calcitonin_versus_cimetidine_or_De_Nol_in_gastric_ulcer_treatment__An_endoscopically_controlled_trial_ DB - PRIME DP - Unbound Medicine ER -